Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Status:
Completed
Trial end date:
2017-06-21
Target enrollment:
Participant gender:
Summary
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter
frequently. Patients who present with opioid withdrawal display symptoms such as agitation,
anxiety, myalgias, abdominal pain, diarrhea, nausea, and vomiting. Currently, the standard
treatment for opioid withdrawal is clonidine (an alpha-2 adrenergic agonist), as well as
supportive cares (anti-emetics, intravenous fluids). Olanzapine is an atypical antipsychotic
that is given frequently in the ED for many of the same symptoms that are seen in patients
who are experiencing opioid withdrawal, however its use in this toxidrome has never been
studied. The hypothesis of this study is that olanzapine is a safe and efficacious option
when compared to clonidine for the treatment of opioid withdrawal in the emergency
department.
Phase:
N/A
Details
Lead Sponsor:
Hennepin Healthcare Research Institute Minneapolis Medical Research Foundation